RxDoctor Payments Data

Eugene Liu, MD

Interventional Pain Medicine · Dobbs Ferry, NYNPI 1467679944

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 23 payments — averaging $46.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$216
  • AbbVie$171
  • Merz North America, Inc.$156
  • Pacira Therapeutics, Inc.$118
  • Pacira Cryotech Incorporated$99
  • Solta Medical, A Division Of Bausch Health US, LLC$92
  • plus $212 from 6 others

What the payments were for

  • Food & beverage$1,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific5$216
AbbVie3$171
Merz North America, Inc.4$156
Pacira Therapeutics, Inc.1$118
Pacira Cryotech Incorporated1$99
Solta Medical, A Division Of Bausch Health US, LLC1$92
Zimmer Biomet1$78
Collegium Pharmaceutical, Inc.3$59
Abbott1$25
Nevro Corp.1$18
Virtus Pharmaceuticals LLC1$16
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,064 in reported general payments places this provider in the 25th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$273,716
Medicare patients
126
Services billed
34,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen14$45,229
OxycontinOxycodone Hcl26$30,230
MovantikNaloxegol Oxalate19$7,724
Oxycodone Hcl293$6,801
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen195$4,499
Buprenorphine11$3,392
Gabapentin222$2,574
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$2,138
Lidocaine13$1,378
Tizanidine Hcl158$1,106
Cyclobenzaprine Hcl118$943
Baclofen80$654
Naproxen47$367
Diclofenac Sodium16$363
Topiramate47$311

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Dobbs Ferry

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →